Our empirical focus concerns GLP1R agonists, which have proven effective for the treatment of type 2 diabetes and obesity (Aroda et al., 2019; Wilding et al., 2021), and for preventing cardiovascular events in people with type 2 diabetes (Marso et al., 2016; Gerstein et al., 2019; Hernandez et al., 2018), with a cardiovascular outcome clinical trial underway in people with obesity (Ryan et al., 2020). Here, GLP1R is linked to obesity disorder.